BioVentrix® Closes $48.5 Million Series A Financing
Financing led by Andera Partners including Cormorant Asset Management, Taglich [...]
New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device [...]
BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer
Brings Extensive Clinical Trial and Patient Care Experience to Senior [...]
FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC® System for the Treatment of Ischemic Heart Failure
Treatment IDE Will Provide Opportunity to Treat Additional Patients in [...]
